Linsitinib

Linsitinib (pronounced lin-SIT-in-ib) is a type of molecular targeted therapy used in the treatment of certain types of cancer. It is also known by its developmental code name OSI-906.

Etymology

The name "Linsitinib" is derived from the Latin word "linum" meaning flax, and "sitin" from the Greek word "sitinos" meaning wheat, symbolizing the drug's ability to target and destroy cancer cells much like wheat is harvested.

Pharmacology

Linsitinib is a small molecule inhibitor of the Insulin receptor and Insulin-like growth factor 1 receptor (IGF-1R). It works by blocking the signals that tell cancer cells to grow and divide, thereby inhibiting the growth of the tumor.

Clinical Use

Linsitinib is currently being studied in clinical trials for its effectiveness in treating various types of cancer, including adrenocortical carcinoma, non-small cell lung cancer, and colorectal cancer. It is not yet approved by the Food and Drug Administration (FDA) for general use.

Side Effects

As with most cancer treatments, Linsitinib can cause side effects. These may include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include hyperglycemia and pneumonitis.

Related Terms

• Molecular targeted therapy
• Insulin receptor
• Insulin-like growth factor 1 receptor
• Adrenocortical carcinoma
• Non-small cell lung cancer
• Colorectal cancer
• Food and Drug Administration
• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Hyperglycemia
• Pneumonitis

External links

• Medical encyclopedia article on Linsitinib
• Wikipedia's article - Linsitinib

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski